BR0210101A - Combinações antineoplásticas - Google Patents

Combinações antineoplásticas

Info

Publication number
BR0210101A
BR0210101A BR0210101-7A BR0210101A BR0210101A BR 0210101 A BR0210101 A BR 0210101A BR 0210101 A BR0210101 A BR 0210101A BR 0210101 A BR0210101 A BR 0210101A
Authority
BR
Brazil
Prior art keywords
antineoplastic
antineoplastic combinations
combinations
neoplasms
treatment
Prior art date
Application number
BR0210101-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Gary Dukart
James Joseph Gibbons Jr
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0210101A publication Critical patent/BR0210101A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0210101-7A 2001-06-01 2002-05-29 Combinações antineoplásticas BR0210101A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01
US29519001P 2001-06-01 2001-06-01
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Publications (1)

Publication Number Publication Date
BR0210101A true BR0210101A (pt) 2004-06-08

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210101-7A BR0210101A (pt) 2001-06-01 2002-05-29 Combinações antineoplásticas

Country Status (17)

Country Link
EP (1) EP1392286A2 (cg-RX-API-DMAC7.html)
JP (1) JP2004532883A (cg-RX-API-DMAC7.html)
KR (1) KR100875611B1 (cg-RX-API-DMAC7.html)
CN (1) CN100496485C (cg-RX-API-DMAC7.html)
AU (2) AU2002259309B2 (cg-RX-API-DMAC7.html)
BR (1) BR0210101A (cg-RX-API-DMAC7.html)
CA (1) CA2447732A1 (cg-RX-API-DMAC7.html)
CO (1) CO5540294A2 (cg-RX-API-DMAC7.html)
EA (1) EA007530B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0400006A2 (cg-RX-API-DMAC7.html)
IL (1) IL158800A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03010907A (cg-RX-API-DMAC7.html)
NO (1) NO20035317L (cg-RX-API-DMAC7.html)
NZ (1) NZ529877A (cg-RX-API-DMAC7.html)
PL (1) PL367267A1 (cg-RX-API-DMAC7.html)
SG (1) SG153647A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002098416A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL231418B1 (pl) 2001-02-19 2019-02-28 Novartis Ag 40-O-( 2-hydroksyetylo)- rapamycyna do zastosowania w leczeniu guzów litych płuc, innych niż nowotwór tkanki limfatycznej
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
MX2007009317A (es) 2005-02-03 2008-01-30 Gen Hospital Corp Metodo para tratar cancer resistente a gefitinib.
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
JP2009516671A (ja) * 2005-11-21 2009-04-23 ノバルティス アクチエンゲゼルシャフト ｍＴＯＲ阻害剤を使用する神経内分泌腫瘍処置
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
KR20140019032A (ko) * 2006-04-05 2014-02-13 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
MX380318B (es) * 2007-03-07 2025-03-12 Abraxis Bioscience Llc Nanoparticula que comprende rapamicina y albumina como agente anticancer.
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2010008744A2 (en) 2008-06-17 2010-01-21 Wyeth Antineoplastic combinations containing hki-272 and vinorelbine
RU2498804C2 (ru) 2008-08-04 2013-11-20 ВАЙЕТ ЭлЭлСи Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物
CN119732959A (zh) * 2024-12-31 2025-04-01 吉林大学 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
DE69209183T2 (de) * 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
PL231418B1 (pl) * 2001-02-19 2019-02-28 Novartis Ag 40-O-( 2-hydroksyetylo)- rapamycyna do zastosowania w leczeniu guzów litych płuc, innych niż nowotwór tkanki limfatycznej

Also Published As

Publication number Publication date
EP1392286A2 (en) 2004-03-03
HUP0400006A2 (hu) 2004-04-28
CO5540294A2 (es) 2005-07-29
PL367267A1 (en) 2005-02-21
AU2002259309B2 (en) 2008-05-01
AU2008202690A1 (en) 2008-07-10
EA200301319A1 (ru) 2004-04-29
NO20035317L (no) 2003-12-22
KR20040025923A (ko) 2004-03-26
MXPA03010907A (es) 2004-02-17
CN1646120A (zh) 2005-07-27
NZ529877A (en) 2006-08-31
CA2447732A1 (en) 2002-12-12
WO2002098416A3 (en) 2003-03-13
JP2004532883A (ja) 2004-10-28
CN100496485C (zh) 2009-06-10
WO2002098416A2 (en) 2002-12-12
KR100875611B1 (ko) 2008-12-24
EA007530B1 (ru) 2006-10-27
IL158800A0 (en) 2004-05-12
SG153647A1 (en) 2009-07-29
NO20035317D0 (no) 2003-11-28

Similar Documents

Publication Publication Date Title
BR0211769A (pt) Combinações antineoplásicas
BR0210101A (pt) Combinações antineoplásticas
BR0115323A (pt) Uso de cci-779 como agente antineoplástico
BRPI0409632A (pt) combinações antineoplásticas
BR0208627A (pt) Combinações antineoplásicas tal como rapamicina junto com gencitabina ou fluorouracila
DE69925133D1 (de) Pyrrolobenzodiazepine
ATE341537T1 (de) Dolastatin 10 derivate
BR0101304B1 (pt) "composição de poliolefina que compreende uma mistura de absorvedores de uv e uso de uma mistura de absorvedores de uv".
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
ECSP034866A (es) Combinaciones antineoplásticas
AR033012A1 (es) Combinaciones antineoplasicas
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
BR0210632A (pt) Tratamento de doença parasìtica
PT1274426E (pt) Uso de tioamida-oxazolidinonas no tratamento da reabsorcao ossea e da osteoporose
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
FI20040531A7 (fi) Insuliiniresistenttien tilojen hoitaminen ja diagnosointi
BR0313230A (pt) Uso de carboxamidas para o tratamento de tinido
DE60136706D1 (de) Ycin-acryloyl derivate und antimetabolische mitteln
IT1302813B1 (it) Dispositivo per la riduzione diretta di ossidi di ferroe relativo procedimento
HU0103040D0 (en) High - level source and it's application
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
ITRM20000107A0 (it) Composizione per la prevenzione e/o il trattamento degli effetti citotossici indotti dall'uso di agenti immunosoppressori.
PT1313500E (pt) Associacoes de dalfopristina/quinupristina com o cefpirome
BR9908664A (pt) O uso do nitroprussiato de sódio e a respectiva aplicação

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.